MCID: CRD119
MIFTS: 65

Cardiac Arrest

Categories: Cardiovascular diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Cardiac Arrest

MalaCards integrated aliases for Cardiac Arrest:

Name: Cardiac Arrest 11 75 28 53 5 14 16 71 31
Cardiopulmonary Arrest 11 53 71
Circulatory Arrest 11 14 71
Heart Arrest 43

Classifications:



External Ids:

Disease Ontology 11 DOID:0060319
ICD9CM 34 427.5
MeSH 43 D006323
SNOMED-CT 68 30298009
ICD10 31 I46 I46.0 I46.9
UMLS 71 C0018790 C0444720 C0600228

Summaries for Cardiac Arrest

Disease Ontology: 11 A congestive heart failure characterized by a sudden stop in effective blood circulation due to the failure of the heart to contract effectively or at all.

MalaCards based summary: Cardiac Arrest, also known as cardiopulmonary arrest, is related to post-cardiac arrest syndrome and ventricular fibrillation, paroxysmal familial, 1, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Cardiac Arrest is CASQ2 (Calsequestrin 2), and among its related pathways/superpathways are Transport of inorganic cations/anions and amino acids/oligopeptides and Beta-2 adrenergic-dependent CFTR expression. The drugs Clonazepam and Lorazepam have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and skeletal muscle, and related phenotypes are muscle and growth/size/body region

Wikipedia: 75 Cardiac arrest is when the heart suddenly and unexpectedly stops beating. It is a medical emergency... more...

Related Diseases for Cardiac Arrest

Diseases in the Cardiac Arrest family:

Post-Cardiac Arrest Syndrome

Diseases related to Cardiac Arrest via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1143)
# Related Disease Score Top Affiliating Genes
1 post-cardiac arrest syndrome 33.3 S100B ENO2
2 ventricular fibrillation, paroxysmal familial, 1 33.0 TNNT2 SCN5A RYR2
3 ventricular tachycardia, catecholaminergic polymorphic, 3 32.3 TRDN RYR2 LCN2 CASQ2
4 cardiac arrhythmia, ankyrin-b-related 32.3 TRDN SCN5A RYR2
5 wolff-parkinson-white syndrome 32.2 TNNT2 SCN5A NPPB MYH7 CASQ2
6 ventricular tachycardia, catecholaminergic polymorphic, 4 32.2 LCN2 CALM1
7 short qt syndrome 32.2 SCN5A RYR2 CASQ2
8 ventricular tachycardia, catecholaminergic polymorphic, 2 32.2 TRDN RYR2 CASQ2
9 progressive familial heart block 32.1 SCN5A DSP
10 long qt syndrome 14 32.1 TRDN SCN5A CALM1
11 timothy syndrome 32.1 TRDN SCN5A RYR2 CASQ2
12 jervell and lange-nielsen syndrome 1 32.1 TRDN SCN5A RYR2 CASQ2
13 ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy 32.1 TRDN RYR2 CASQ2 CALM1
14 long qt syndrome 3 32.1 TRDN SCN5A RYR2 CASQ2
15 cardiac conduction defect 32.1 SCN5A RYR2 MYH7 DSP CEP85L
16 heart valve disease 32.0 TNNT2 NPPB MYH7
17 long qt syndrome 15 32.0 TRDN CALM1
18 myocarditis 32.0 TNNT2 NPPB MYH7 DSP
19 long qt syndrome 2 32.0 TRDN SCN5A RYR2 CASQ2 CALM1
20 malignant hyperthermia 32.0 TRDN SCN5A RYR2 MYH7 CASQ2
21 myocardial infarction 31.9 TNNT2 SCN5A S100B NPPB MYH7 LCN2
22 neonatal hypoxic and ischemic brain injury 31.9 ENO2 CKB
23 long qt syndrome 1 31.8 TRDN TNNT2 SCN5A RYR2 MYH7 DSP
24 syncope 31.8 TNNT2 SCN5A RYR2
25 catecholaminergic polymorphic ventricular tachycardia 31.8 TRDN TNNT2 SCN5A RYR2 MYH7 DSP
26 brugada syndrome 31.6 TRDN TNNT2 SCN5A RYR2 PLN MYH7
27 lipoprotein quantitative trait locus 31.5 TNNT2 SCN5A RYR2 NPPB MYH7 CASQ2
28 third-degree atrioventricular block 31.4 SCN5A RYR2 NPPB CASQ2
29 cardiomyopathy, familial hypertrophic, 1 31.4 TNNT2 SCN5A RYR2 MYH7 CASQ2
30 atrioventricular block 31.3 TNNT2 SCN5A RYR2 NPPB
31 long qt syndrome 31.1 TRDN TNNT2 SCN5A RYR2 MYH7 DSP
32 progressive familial heart block, type ia 31.1 SCN5A DSP
33 aortic valve disease 2 31.1 TNNT2 NPPB MYH7
34 congestive heart failure 31.0 TNNT2 SCN5A PLN NPPB MYH7
35 intracranial hypertension 31.0 S100B NPPB ENO2
36 left bundle branch hemiblock 31.0 TNNT2 SCN5A RYR2 NPPB DSP
37 heart septal defect 31.0 TNNT2 NPPB MYH7
38 mitral valve insufficiency 30.9 TNNT2 NPPB MYH7 CKB
39 right bundle branch block 30.8 TNNT2 SCN5A RYR2 NPPB DSP
40 intracranial berry aneurysm 30.8 S100B HMOX1 ENO2
41 asphyxia neonatorum 30.8 S100B ENO2
42 sudden infant death syndrome 30.8 SCN5A RYR2 PLN CEP85L
43 inferior myocardial infarction 30.7 TNNT2 NPPB
44 acute myocarditis 30.7 TNNT2 NPPB DSP
45 atrial heart septal defect 30.7 TNNT2 SCN5A NPPB MYH7
46 arrhythmogenic right ventricular cardiomyopathy 30.6 TNNT2 SCN5A RYR2 PLN MYH7 DSP
47 pericarditis 30.6 TNNT2 NPPB G6PD ENO2
48 ebstein anomaly 30.6 SCN5A NPPB MYH7
49 hypertrophic cardiomyopathy 30.6 TRDN TNNT2 SCN5A RYR2 PPA2 PLN
50 hypoplastic left heart syndrome 30.5 TNNT2 NPPB MYH7 LCN2

Comorbidity relations with Cardiac Arrest via Phenotypic Disease Network (PDN): (show all 31)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Myocardial Infarction
Aortic Aneurysm Aortic Valve Disease 1
Bronchitis Cardiogenic Shock
Chronic Kidney Disease Decubitus Ulcer
Deficiency Anemia Disseminated Intravascular Coagulation
Familial Atrial Fibrillation First-Degree Atrioventricular Block
Generalized Atherosclerosis Heart Disease
Hypertension, Essential Hyperuricemia, Pulmonary Hypertension, Renal Failure, and Alkalosis Syndrome
Intermediate Coronary Syndrome Kidney Disease
Mitral Valve Disease Ocular Motor Apraxia
Peripheral Vascular Disease Progressive Familial Heart Block, Type Ia
Protein-Energy Malnutrition Pulmonary Hypertension, Primary, 1
Respiratory Failure Sinoatrial Node Disease
Third-Degree Atrioventricular Block Tricuspid Valve Disease
Ventricular Fibrillation, Paroxysmal Familial, 1

Graphical network of the top 20 diseases related to Cardiac Arrest:



Diseases related to Cardiac Arrest

Symptoms & Phenotypes for Cardiac Arrest

UMLS symptoms related to Cardiac Arrest:


angina pectoris; chest pain; edema

MGI Mouse Phenotypes related to Cardiac Arrest:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 9.85 CASQ2 DSP HMOX1 MYH7 NPPB PLN
2 growth/size/body region MP:0005378 9.77 CALM1 CEP85L CKB DSP ENO2 G6PD
3 cardiovascular system MP:0005385 9.44 CALM1 CASQ2 DSP G6PD HMOX1 LCN2

Drugs & Therapeutics for Cardiac Arrest

Drugs for Cardiac Arrest (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 306)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
2
Lorazepam Approved Phase 4 846-49-1 3958
3
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
4
Cangrelor Approved Phase 4 163706-06-7 9854012
5
Ticagrelor Approved Phase 4 274693-27-5 9871419
6
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
7
Clavulanic acid Approved, Vet_approved Phase 4 58001-44-8 5280980
8
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
9
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
10
Etomidate Approved Phase 4 33125-97-2 667484
11
Sulfamethazine Approved, Investigational, Vet_approved Phase 4 57-68-1 5327
12
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
13
Prasugrel Hydrochloride Phase 4 389574-19-0
14 Neurotransmitter Agents Phase 4
15 Adrenergic alpha-Agonists Phase 4
16 Adrenergic Agonists Phase 4
17 Adrenergic Agents Phase 4
18 Excitatory Amino Acid Antagonists Phase 4
19 Anesthetics, Intravenous Phase 4
20 Anesthetics, Dissociative Phase 4
21 Dermatologic Agents Phase 4
22 Purinergic P2Y Receptor Antagonists Phase 4
23 Amoxicillin-Potassium Clavulanate Combination Phase 4
24 beta-Lactamase Inhibitors Phase 4
25
Epoetin Alfa Phase 4
26 Keratolytic Agents Phase 4
27
Pyrithione zinc Phase 4 13463-41-7 415267
28 Hypnotics and Sedatives Phase 4
29 Hematinics Phase 4
30 Mineralocorticoids Phase 4
31 Mineralocorticoid Receptor Antagonists Phase 4
32
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
33
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
34
Prednisolone Approved, Vet_approved Phase 3 50-24-8 4894 5755
35
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5 1875
36
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 4159 6741
37
Hydrocortisone succinate Approved Phase 3 2203-97-6 3643
38
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
39
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 3640 5754
40
Amiodarone Approved, Investigational Phase 3 1951-25-3 2157
41
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
42
Rocuronium Approved Phase 3 119302-91-9, 143558-00-3 441290
43
Midazolam Approved, Illicit Phase 3 59467-70-8 4192
44
Quinidine Approved, Investigational Phase 3 56-54-2, 130-95-0, 804-63-7 1065 441074 3034034 8549
45
Imipramine Approved Phase 3 50-49-7 3696
46
Procainamide Approved Phase 3 51-06-9 4913
47
Sotalol Approved Phase 3 959-24-0, 3930-20-9 5253
48
Mexiletine Approved, Investigational Phase 3 5370-01-4, 31828-71-4 4178
49
Propafenone Approved Phase 3 34183-22-7, 54063-53-5 4932
50
Moricizine Approved, Investigational, Withdrawn Phase 3 31883-05-3 34633

Interventional clinical trials:

(show top 50) (show all 861)
# Name Status NCT ID Phase Drugs
1 Comparison of the Effect of Vasopressin, Steroid, and Epinephrine Treatment in Patients With Out-of-hospital Cardiac Arrest: Multi-center, Double Blind, Randomized, Placebo-controlled Study Unknown status NCT03317197 Phase 4 Control Group;Experimental Group 1;Experimental Group 2;Experimental Group 3
2 The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia Unknown status NCT01083784 Phase 4 Use of prophylactic anticonvulsants (valproate, clonazepam);Control group
3 Combining Propofol With Therapeutic Hypothermia for Improving Survival and Neurological Prognoses in Patients Resuscitated From Cardiac Arrest Unknown status NCT02367755 Phase 4 Propofol;Lorazepam
4 Does the Early Use of Sodium Bicarbonate Improve Results of Cardiopulmonary Resuscitation Following Out-of-Hospital Cardiac Arrest - a Prospective, Controlled Clinical Trial Unknown status NCT01377337 Phase 4 sodium bicarbonate
5 Pharmacokinetic/Pharmacodynamic Effects of add-on Antiplatelet Therapy With Parenteral Cangrelor as Compared to Standard Dual Antiplatelet Treatment in Patients With ST-elevation Myocardial Infarction Complicated by Out-of-hospital Cardiac Arrest and Treated With Targeted Temperature Management Unknown status NCT03273075 Phase 4 Cangrelor;Placebo;Prasugrel;Ticagrelor
6 Immediate Unselected Coronary Angiography Versus Delayed Triage in Survivors of Out-of-hospital Cardiac Arrest Without ST-segment Elevation Completed NCT02750462 Phase 4
7 Comparison of Epinephrine Associated With Vasopressin vs Epinephrine Alone in the Treatment of Out-of-Hospital Cardiac Arrests Completed NCT00127907 Phase 4 epinephrine (1 mg/1 mL);arginine-vasopressin (40 UI/2 mL)
8 Platelet Inhibition With Cangrelor in Comatose Survivors of Out-of-hospital Cardiac Arrest Undergoing Primary Percutaneous Coronary Intervention Completed NCT04005729 Phase 4 Cangrelor 50 MG
9 Prophylactic Versus Clinically-driven Antibiotics in Comatose Survivors of Out-of-hospital Cardiac Arrest Completed NCT02899507 Phase 4 Amoxicillin-Clavulanic acid
10 Pilot Randomized Clinical Trial Comparing the Efficacy of Two Different Hypothermia Temperatures for Treatment of Comatose Patients Recovered From an Out-of-hospital Cardiac Arrest Completed NCT01155622 Phase 4
11 Trial Of Continuous Compressions Versus Standard CPR In Patients With Out-Of-Hospital Cardiac Arrest Completed NCT01372748 Phase 4
12 Clinical Evaluation of Intraosseous and Intravenous Access for Cardiac Arrest Treatment in Emergency Ambulances In Singapore Completed NCT02088736 Phase 4
13 Out-of-Hospital Intubation in Emergency Conditions With Either Metal Single Use or Reusable Laryngoscope Blades : Impact on Intubation Difficulties Completed NCT00644722 Phase 4
14 Clinical and Neurological Outcome With Two Different Cooling Methods (Invasive and Non-invasive) After Sudden Cardiac Arrest Completed NCT00843297 Phase 4
15 A Phased Prospective Clinical Study Comparing Controlled Therapeutic Hypothermia Post Resuscitation After Cardiac Arrest Using External and Internal Cooling to Standard Intensive Care Unit Therapy Completed NCT00827957 Phase 4
16 Interest for a Relative of Seeing Himself Proposing to Witness Resuscitation of a Family Member Victim of a Cardiac Arrest Completed NCT01009606 Phase 4
17 Is Extensive Electrophysiological Testing Before, During and After ICD-Implantation Still Necessary in Patients After Survived Cardiac Arrest? A Prospective Randomised Multi-centre Trial. Completed NCT00180362 Phase 4
18 Transthoracic Incremental Monophasic Versus Biphasic by Emergency Responders (TIMBER) Completed NCT00101881 Phase 4
19 Comparison of Antiplatelet Therapy With Clopidogrel and Ticagrelor in Patients After Cardiac Arrest Treated With Therapeutic Hypothermia Completed NCT02224274 Phase 4 Clopidogrel;Ticagrelor
20 Clinical Interest of Endovascular Cooling in the Management of Cardiac Arrest: Impact on Mortality in a Randomized Medico-economical Trial (the ICEREA Study) Completed NCT00392639 Phase 4
21 Evaluation of the Effects and Plasma Concentration of the Potent Platelet Inhibitor Ticagrelor, After Crushed and Non-crushed Intake, After Semi-urgent Coronary Bypass and in Patients After Cardiac Arrest. Completed NCT02341729 Phase 4 ticagrelor
22 Prevention of Acute Kidney Injury by Erythropoietin in Patients Undergoing Thoracic Aorta Surgery With Hypothermic Cardiac Arrest Completed NCT01369732 Phase 4 recombinant human erythropoietin;saline
23 Etomidate Versus Ketamine for Emergency Endotracheal Intubation: a Prospective Randomized Clinical Trial Completed NCT02643381 Phase 4 Etomidate;Ketamine
24 Effect of Intraoperative Dexmedetomidine on Lung Protection Following Thoracic Aorta Surgery With Hypothermic Circulatory Arrest: a Randomized Clinical Trial Completed NCT02678728 Phase 4 Dexmedetomidine;normal saline
25 A Comprehensive Individually Tailored Rehabilitation Intervention Focusing on Supporting Labour Marked Participation for Survivors of Out-of-hospital Cardiac Arrest. A Multicenter Pragmatic Randomized Controlled Trial Recruiting NCT05173740 Phase 4
26 Arrhythmia Prevention in High Risk Cardiovascular Patients Using Targeted Potassium Levels Recruiting NCT03833089 Phase 4
27 Intravenous vs. Intraosseous Vascular Access During Out-of-Hospital Cardiac Arrest - A Randomized Clinical Trial Recruiting NCT05205031 Phase 4
28 CanROC Epinephrine Dose: Optimal Versus Standard Evaluation Trial (CanROC EpiDOSE Trial) Not yet recruiting NCT03826524 Phase 4 Epinephrine
29 Bicarbonate for In-Hospital Cardiac Arrest - A Randomized, Double-Blind, Placebo-Controlled Trial Not yet recruiting NCT05564130 Phase 4 Sodium bicarbonate;Sodium chloride
30 Prehospital Laryngeal Tube vs. Bag-Valve Mask Ventilation Used by Paramedics During CPR- A Prospective, Controlled, Randomised, Multi-center Trial Terminated NCT01718795 Phase 4
31 Pre Hospital Evaluation of Video Laryngoscopy : a Comparative Study of Macintosh and GLIDESCOPE Ranger® Withdrawn NCT01374061 Phase 4
32 Neuroprotective Effect of Desflurane in the Experimental Study: the Impact if Desflurane Preconditioning on the Content of the Phosphorylated Form of GSK-3b in the Neurons of the Rat's Brain in the Model of Ischemia/Reperfusion Withdrawn NCT04287842 Phase 4 Desflurane;Sevoflurane
33 XePOHCAS - Xenon by Inhalation for Post Out of Hospital Cardiac Arrest Syndrome Unknown status NCT03176186 Phase 3
34 LUcas Continuous Chest Compressions in Out-of-hospital Cardiac Arrest Treatment. The LUCAT Trial Unknown status NCT01521208 Phase 3
35 A Multicentre Prospective Randomised Study Comparing the Efficacy of High Versus Low Biphasic Energy Defibrillation in Patients With Cardiac Arrest Unknown status NCT00429611 Phase 3
36 Arrested Versus Beating Heart Techniques in Coronary Revascularisation: Randomized Clinical Trial in Unselected Patients Unknown status NCT00999089 Phase 3
37 Study of the Use of Mild Hypothermia in Out-of-hospital Cardiac Arrest Using a Rapid Infusion of 2 Liters of Cold Normal Saline Completed NCT00391469 Phase 2, Phase 3 Rapid infusion of cold normal saline
38 Automated External Defibrillator (AED) Use in Out-of-Hospital Cardiac Arrest: A New Algorithm Named "One Shock Per Minute" Completed NCT00139542 Phase 3
39 CYclosporine A in Non-shockable Out-of-hospital Cardiac Arrest ResUScitation Completed NCT01595958 Phase 3 Cyclosporine A
40 The RINSE Trial: Rapid Infusion of Cold Saline During CPR for Patients With Cardiac Arrest Completed NCT01173393 Phase 3
41 Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation (VF) or Ventricular Tachycardia (VT) Completed NCT01401647 Phase 3 amiodarone;Lidocaine
42 Reduction of no Flow Time During Out of Hospital Cardiac Arrest by Using Laryngeal Tube for Airway Management by Nurses. Completed NCT01295749 Phase 3
43 Randomized Clinical Trial of Sodium Nitrite for Out of Hospital Cardiac Arrest Completed NCT03452917 Phase 2, Phase 3 Placebo;sodium nitrite 45 mg;sodium nitrite 60 mg
44 InterLeukine Ancillary Study of the Therapeutic Hypothermia After Nonshockable Cardiac Arrest Trial. Completed NCT02711098 Phase 3
45 Early High-dose Erythropoietin Therapy and Hypothermia After Out-of-hospital Cardiac Arrest: A Matched Control Study Completed NCT00719498 Phase 3 Epo-alpha
46 NSE Ancillary Study of The Therapeutic Hypothermia After Nonshockable Cardiac Arrest Trial. Completed NCT02722473 Phase 3
47 Hemodynamic Efficiency of an Hemodialysis Treatment With High Permeability (HDHP) During the Early Period of Post-resuscitation Shock Completed NCT00780299 Phase 3
48 Vasopressin, Epinephrine, and Corticosteroids for Inhospital Cardiac Arrest: A Multicenter Randomized Controlled Trial Completed NCT00729794 Phase 3 Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone;Standard CPR Protocol with Epinephrine and two Placebos
49 High Dose of Erythropoietin Analogue After Cardiac Arrest: a Multicentre, Randomised, Controlled Trial (Epo-ACR-02 Trial) Completed NCT00999583 Phase 3 EPOETINE ALPHA
50 A Randomised, Double-blinded Multi-centre Trial Comparing Vasopressin and Adrenaline in Patients With Cardiac Arrest at the Emergency Department. (Preadmission Intravenous Vasopressin, Adrenaline Outcome Trial: PIVOT vII) Completed NCT00358579 Phase 3 Adrenaline;Vasopressin

Search NIH Clinical Center for Cardiac Arrest

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Atropine
Atropine Sulfate
Calcium Chloride
Calcium gluceptate
Calcium Gluconate
CALCIUM GLUCONATE PWDR
Epinephrine
epinephrine bitartrate
epinephrine hydrochloride
epinephryl borate
Methylatropine nitrate
Racepinephrine Hydrochloride
Sodium Bicarbonate
SODIUM BICARBONATE PWDR

Cochrane evidence based reviews: heart arrest

Genetic Tests for Cardiac Arrest

Genetic tests related to Cardiac Arrest:

# Genetic test Affiliating Genes
1 Cardiac Arrest 28

Anatomical Context for Cardiac Arrest

Organs/tissues related to Cardiac Arrest:

MalaCards : Heart, Brain, Skeletal Muscle, Kidney, Lung, Spinal Cord, Liver

Publications for Cardiac Arrest

Articles related to Cardiac Arrest:

(show top 50) (show all 38197)
# Title Authors PMID Year
1
Interpreting secondary cardiac disease variants in an exome cohort. 5
23861362 2013
2
Familial evaluation in arrhythmogenic right ventricular cardiomyopathy: impact of genetics and revised task force criteria. 5
21606390 2011
3
Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. 5
12639993 2003
4
Neuron specific enolase and S-100B as predictors of outcome after cardiac arrest and induced hypothermia. 53 62
19467754 2009
5
Neuron-specific enolase and S-100B are associated with neurologic outcome after pediatric cardiac arrest. 53 62
19307814 2009
6
Predictive power of serum NSE and OHCA score regarding 6-month neurologic outcome after out-of-hospital ventricular fibrillation and therapeutic hypothermia. 53 62
18954930 2009
7
Serum neuron specific enolase to predict neurological outcome after cardiopulmonary resuscitation: a critically appraised topic. 53 62
19131859 2009
8
[Role of neuron specific enolase and S100 protein in evaluation of brain damage in patients resuscitated from cardiac arrest]. 53 62
18093437 2007
9
Biochemical markers (NSE, S-100, IL-8) as predictors of neurological outcome in patients after cardiac arrest and return of spontaneous circulation. 53 62
17482335 2007
10
Prediction of cognitive dysfunction after resuscitation from out-of-hospital cardiac arrest using serum neuron-specific enolase and protein S-100. 53 62
17502328 2007
11
2006 Curt P. Richter award winner: Social influences on stress responses and health. 53 62
17590276 2007
12
Carnitine-acylcarnitine translocase deficiency in three neonates presenting with rapid deterioration and cardiac arrest. 53 62
17277394 2007
13
Oxidative stress reversibly inactivates myocardial enzymes during cardiac arrest. 53 62
16920803 2007
14
Cardiac ryanodine receptor gene (hRyR2) mutation underlying catecholaminergic polymorphic ventricular tachycardia in a Chinese adolescent presenting with sudden cardiac arrest and cardiac syncope. 53 62
17199967 2006
15
Allelic variants of SCN5A and risk of sudden cardiac arrest in patients with coronary artery disease. 53 62
16731473 2006
16
Disorders of carnitine transport and the carnitine cycle. 53 62
16602102 2006
17
Serum neuron-specific enolase as early predictor of outcome after in-hospital cardiac arrest: a cohort study. 53 62
16978415 2006
18
Changes of cytoskeletal proteins in ischaemic brain under cardiac arrest and reperfusion conditions. 53 62
16823696 2006
19
Ability of neuron-specific enolase to predict survival to hospital discharge after successful cardiopulmonary resuscitation. 53 62
17175624 2006
20
Outcome after cardiac arrest: predictive values and limitations of the neuroproteins neuron-specific enolase and protein S-100 and the Glasgow Coma Scale. 53 62
15797275 2005
21
Up-regulation of a growth arrest and DNA damage protein (GADD34) in the ischaemic human brain: implications for protein synthesis regulation and DNA repair. 53 62
15541008 2004
22
[Stem cell mobilization after coronary artery bypass grafting]. 53 62
15253141 2004
23
Serum neuron-specific enolase and S-100B protein in cardiac arrest patients treated with hypothermia. 53 62
14631087 2003
24
Spatial resolution of phospholipid scramblase 1 (PLSCR1), caspase-3 activation and DNA-fragmentation in the human hippocampus after cerebral ischemia. 53 62
12605885 2003
25
Natural history of Brugada syndrome: insights for risk stratification and management. 53 62
11901046 2002
26
Serum levels of the brain-derived proteins S-100 and NSE predict long-term outcome after cardiac arrest. 53 62
11382525 2001
27
Apical hypertrophic cardiomyopathy due to a de novo mutation Arg719Trp of the beta-myosin heavy chain gene and cardiac arrest in childhood. A case report and family study. 53 62
10957787 2000
28
Time course of serum neuron-specific enolase. A predictor of neurological outcome in patients resuscitated from cardiac arrest. 53 62
10436107 1999
29
Monitoring of extracellular aspartate aminotransferase and troponin T by microdialysis during and after cardioplegic heart arrest. 53 62
10754346 1999
30
Different intracellular compartmentations of cardiac troponins and myosin heavy chains: a causal connection to their different early release after myocardial damage. 53 62
9732976 1998
31
Creatine kinase-mb fraction and cardiac troponin T to diagnose acute myocardial infarction after cardiopulmonary resuscitation. 53 62
8890819 1996
32
Corticosteroid and immune responses to cardiac surgery. 53 62
8837293 1996
33
Creatine kinase and creatine kinase-MB release after nontraumatic cardiac arrest. 53 62
8610606 1996
34
[Hypoxic brain damage after prolonged cardiac arrest during anesthesia--changes in CT and serum NSE concentration]. 53 62
7933514 1994
35
CSF and serum brain-specific creatine kinase isoenzyme (CK-BB), neuron-specific enolase (NSE) and neural cell adhesion molecule (NCAM) as prognostic markers for hypoxic brain injury after cardiac arrest in man. 53 62
8509798 1993
36
Determinants of elevated creatine kinase activity and creatine kinase MB-fraction following cardiopulmonary resuscitation. 53 62
1582302 1992
37
Evaluation of hypoxic brain injury with spinal fluid enzymes, lactate, and pyruvate. 53 62
1541099 1992
38
Changes of neuron-specific enolase concentration in plasma after cardiac arrest and resuscitation. 53 62
1958265 1991
39
The critical care literature 2021. 62
36306647 2023
40
Role of adjunct anticoagulant or thrombolytic therapy in cardiac arrest without ST-segment-elevation or percutaneous coronary intervention: A systematic review and meta-analysis. 62
36279808 2023
41
Be careful regarding the interpretation of shock index and modified shock index in out-of-hospital cardiac arrest survivors. 62
36175264 2023
42
The impact of COVID-19 pandemic on out-of-hospital cardiac arrest system-of-care: Which survival chain factor contributed the most? 62
36327751 2023
43
Cautions for hypernatremia interpretation regarding long-term neurological outcomes in out-of-hospital cardiac arrest survivors. 62
36243550 2023
44
TEE guided REBOA deflation following ROSC for non-traumatic cardiac arrest. 62
36280542 2023
45
Echocardiographic Characteristics of Cardiogenic Shock Patients with and Without Cardiac Arrest. 62
35656768 2023
46
Sudden severe left ventricular assist device inflow cannula obstruction caused by huge thrombus after closure of mechanical aortic valve: case report. 62
35445295 2022
47
Predictors and Hospital Outcomes in Pregnant Patients Undergoing Extracorporeal Membrane Oxygenation: A Nationwide Study. 62
36384013 2022
48
Use of On-Site Digital Subtraction Angiography for Left Subclavian Artery Management During Hybrid Aortic Arch Repair in DeBakey I Dissection. 62
35012388 2022
49
A comparison of single and double arterial cannulation for cardiopulmonary bypass for acute type A aortic surgery: A single center, retrospective observational study. 62
36464941 2022
50
Pediatic code blue event anaylsis: Performance of non-acute health-care providers. 62
35912470 2022

Variations for Cardiac Arrest

ClinVar genetic disease variations for Cardiac Arrest:

5 (show all 37)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 DSP NM_004415.4(DSP):c.2821C>T (p.Arg941Ter) SNV Likely Pathogenic
180326 rs730880082 GRCh37: 6:7577219-7577219
GRCh38: 6:7576986-7576986
2 CEP85L, PLN NM_002667.5(PLN):c.116T>G (p.Leu39Ter) SNV Likely Pathogenic
13637 rs111033560 GRCh37: 6:118880200-118880200
GRCh38: 6:118559037-118559037
3 DSP NM_004415.4(DSP):c.2260G>A (p.Glu754Lys) SNV Uncertain Significance
180323 rs730880080 GRCh37: 6:7574448-7574448
GRCh38: 6:7574215-7574215
4 AKAP9 NM_005751.5(AKAP9):c.1067A>T (p.Asp356Val) SNV Uncertain Significance
222487 rs533277424 GRCh37: 7:91630298-91630298
GRCh38: 7:92000984-92000984
5 HCN4 NM_005477.3(HCN4):c.2197G>A (p.Val733Ile) SNV Uncertain Significance
222648 rs376631391 GRCh37: 15:73616237-73616237
GRCh38: 15:73323896-73323896
6 ANK2 NM_001148.6(ANK2):c.5509G>A (p.Ala1837Thr) SNV Uncertain Significance
222498 rs199527708 GRCh37: 4:114275283-114275283
GRCh38: 4:113354127-113354127
7 DSG2 NM_001943.5(DSG2):c.437G>T (p.Arg146Leu) SNV Uncertain Significance
44317 rs113451409 GRCh37: 18:29101120-29101120
GRCh38: 18:31521157-31521157
8 TRPM4 NM_017636.4(TRPM4):c.1069C>T (p.Arg357Trp) SNV Uncertain Significance
222852 rs764690335 GRCh37: 19:49675284-49675284
GRCh38: 19:49172027-49172027
9 DSG2 NM_001943.5(DSG2):c.1063G>A (p.Ala355Thr) SNV Uncertain Significance
191629 rs201046640 GRCh37: 18:29110998-29110998
GRCh38: 18:31531035-31531035
10 DSP NM_004415.4(DSP):c.2047G>A (p.Glu683Lys) SNV Uncertain Significance
222574 rs775181391 GRCh37: 6:7572218-7572218
GRCh38: 6:7571985-7571985
11 ANK2 NM_001148.6(ANK2):c.7458C>G (p.His2486Gln) SNV Uncertain Significance
222502 rs776972443 GRCh37: 4:114277232-114277232
GRCh38: 4:113356076-113356076
12 KCNJ8 NM_004982.4(KCNJ8):c.83G>C (p.Arg28Pro) SNV Uncertain Significance
222678 rs768851540 GRCh37: 12:21926468-21926468
GRCh38: 12:21773534-21773534
13 CACNB2 NM_201596.3(CACNB2):c.1642G>A (p.Gly548Ser) SNV Uncertain Significance
180290 rs730880059 GRCh37: 10:18828312-18828312
GRCh38: 10:18539383-18539383
14 CACNB2 NM_201596.3(CACNB2):c.1206+3A>T SNV Uncertain Significance
180291 rs200174877 GRCh37: 10:18823159-18823159
GRCh38: 10:18534230-18534230
15 AKAP9 NM_005751.5(AKAP9):c.1099G>A (p.Val367Met) SNV Uncertain Significance
180260 rs138161478 GRCh37: 7:91630330-91630330
GRCh38: 7:92001016-92001016
16 AKAP9 NM_005751.5(AKAP9):c.11378C>G (p.Ser3793Cys) SNV Uncertain Significance
180266 rs730880044 GRCh37: 7:91735039-91735039
GRCh38: 7:92105725-92105725
17 ANK2 NM_001148.6(ANK2):c.6206G>A (p.Arg2069His) SNV Uncertain Significance
180270 rs149645600 GRCh37: 4:114275980-114275980
GRCh38: 4:113354824-113354824
18 MYH6 NM_002471.4(MYH6):c.4713G>T (p.Lys1571Asn) SNV Uncertain Significance
180427 rs730880151 GRCh37: 14:23855770-23855770
GRCh38: 14:23386561-23386561
19 SLMAP NM_001377540.1(SLMAP):c.2020+1G>A SNV Uncertain Significance
222824 rs869025527 GRCh37: 3:57898429-57898429
GRCh38: 3:57912702-57912702
20 MYOM1 NM_003803.4(MYOM1):c.3708C>A (p.Ser1236Arg) SNV Uncertain Significance
222745 rs869025489 GRCh37: 18:3100176-3100176
GRCh38: 18:3100178-3100178
21 AKAP9 NM_005751.5(AKAP9):c.11276C>T (p.Pro3759Leu) SNV Uncertain Significance
222492 rs869025356 GRCh37: 7:91732086-91732086
GRCh38: 7:92102772-92102772
22 ANK2 NM_001148.6(ANK2):c.7577C>T (p.Ser2526Leu) SNV Uncertain Significance
222503 rs762909298 GRCh37: 4:114277351-114277351
GRCh38: 4:113356195-113356195
23 DPP6 NM_130797.4(DPP6):c.1039G>A (p.Ala347Thr) SNV Uncertain Significance
222554 rs770646362 GRCh37: 7:154564555-154564555
GRCh38: 7:154772845-154772845
24 VCL NM_014000.3(VCL):c.1559G>A (p.Arg520Gln) SNV Uncertain Significance
222888 rs757009736 GRCh37: 10:75855429-75855429
GRCh38: 10:74095671-74095671
25 CACNB2 NM_201596.3(CACNB2):c.1594T>G (p.Ser532Ala) SNV Uncertain Significance
222520 rs869025371 GRCh37: 10:18828264-18828264
GRCh38: 10:18539335-18539335
26 RYR2 NM_001035.3(RYR2):c.13759A>C (p.Ile4587Leu) SNV Uncertain Significance
180504 rs730880198 GRCh37: 1:237955600-237955600
GRCh38: 1:237792300-237792300
27 SCN5A NM_000335.5(SCN5A):c.559A>G (p.Thr187Ala) SNV Uncertain Significance
222801 rs869025517 GRCh37: 3:38662386-38662386
GRCh38: 3:38620895-38620895
28 DSP NM_004415.4(DSP):c.7249G>T (p.Asp2417Tyr) SNV Uncertain Significance
222585 rs760501352 GRCh37: 6:7584744-7584744
GRCh38: 6:7584511-7584511
29 RYR2 NM_001035.3(RYR2):c.378T>A (p.Ser126Arg) SNV Uncertain Significance
222783 rs869025507 GRCh37: 1:237532902-237532902
GRCh38: 1:237369602-237369602
30 DSG2-AS1, DSG2 NM_001943.5(DSG2):c.2188A>G (p.Thr730Ala) SNV Uncertain Significance
222564 rs780650226 GRCh37: 18:29122669-29122669
GRCh38: 18:31542706-31542706
31 SCN5A NM_000335.5(SCN5A):c.5072T>C (p.Phe1691Ser) SNV Uncertain Significance
222813 rs869025521 GRCh37: 3:38592788-38592788
GRCh38: 3:38551297-38551297
32 TTN NM_001267550.2(TTN):c.29230C>T (p.Arg9744Cys) SNV Likely Benign
46820 rs375266859 GRCh37: 2:179571371-179571371
GRCh38: 2:178706644-178706644
33 CACNA2D1 NM_000722.4(CACNA2D1):c.2264G>C (p.Ser755Thr) SNV Likely Benign
180288 rs151327713 GRCh37: 7:81599241-81599241
GRCh38: 7:81969925-81969925
34 DSC2 NM_024422.6(DSC2):c.1073C>T (p.Thr358Ile) SNV Likely Benign
46160 rs139399951 GRCh37: 18:28662896-28662896
GRCh38: 18:31082930-31082930
35 MYBPC3 NM_000256.3(MYBPC3):c.3392T>C (p.Ile1131Thr) SNV Likely Benign
42711 rs370890951 GRCh37: 11:47354463-47354463
GRCh38: 11:47332912-47332912
36 SCN5A NM_000335.5(SCN5A):c.1715C>A (p.Ala572Asp) SNV Likely Benign
67683 rs36210423 GRCh37: 3:38645378-38645378
GRCh38: 3:38603887-38603887
37 RBM20 NM_001134363.3(RBM20):c.2662G>A (p.Asp888Asn) SNV Benign
43995 rs201370621 GRCh37: 10:112581039-112581039
GRCh38: 10:110821281-110821281

Expression for Cardiac Arrest

Search GEO for disease gene expression data for Cardiac Arrest.

Pathways for Cardiac Arrest

Pathways related to Cardiac Arrest according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.93 CALM1 CASQ2 HMOX1 LCN2 PLN RYR2
2
Show member pathways
12.28 TNNT2 RYR2 PLN CALM1
3
Show member pathways
12.23 TRDN TNNT2 SCN5A RYR2 PLN CASQ2
4 12.2 SCN5A S100B ENO2 CALM1
5
Show member pathways
12.11 RYR2 PLN CASQ2 CALM1
6
Show member pathways
12.02 TRDN RYR2 PLN CASQ2 CALM1
7 11.68 S100B PLN CALM1
8 10.8 NPPB MYH7
9 10.76 SCN5A RYR2 PLN DSP CASQ2

GO Terms for Cardiac Arrest

Cellular components related to Cardiac Arrest according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Z disc GO:0030018 9.97 SCN5A RYR2 MYH7 CASQ2
2 sarcoplasmic reticulum GO:0016529 9.86 CASQ2 PLN RYR2 TRDN
3 calcium channel complex GO:0034704 9.8 RYR2 CASQ2 CALM1
4 sarcoplasmic reticulum lumen GO:0033018 9.71 TRDN CASQ2
5 sarcomere GO:0030017 9.7 TNNT2 RYR2 MYH7 CALM1
6 junctional sarcoplasmic reticulum membrane GO:0014701 9.43 TRDN RYR2 CASQ2
7 sarcoplasmic reticulum membrane GO:0033017 9.23 TRDN RYR2 PLN CASQ2

Biological processes related to Cardiac Arrest according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 cellular calcium ion homeostasis GO:0006874 10.03 TRDN RYR2 PLN CASQ2
2 substantia nigra development GO:0021762 9.95 G6PD CKB CALM1
3 cellular response to caffeine GO:0071313 9.87 RYR2 CASQ2
4 negative regulation of ATP-dependent activity GO:0032780 9.86 TNNT2 PLN
5 regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion GO:0010881 9.86 RYR2 PLN CASQ2 CALM1
6 muscle filament sliding GO:0030049 9.85 TNNT2 MYH7
7 detection of calcium ion GO:0005513 9.85 RYR2 CASQ2 CALM1
8 positive regulation of ryanodine-sensitive calcium-release channel activity GO:0060316 9.84 TRDN CALM1
9 release of sequestered calcium ion into cytosol by sarcoplasmic reticulum GO:0014808 9.83 TRDN RYR2
10 regulation of cardiac muscle cell membrane potential GO:0086036 9.81 PLN TRDN
11 regulation of cell communication by electrical coupling GO:0010649 9.8 TRDN CASQ2
12 negative regulation of ryanodine-sensitive calcium-release channel activity GO:0060315 9.8 TRDN CASQ2 CALM1
13 Purkinje myocyte to ventricular cardiac muscle cell signaling GO:0086029 9.71 CASQ2 RYR2
14 regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum GO:0010880 9.7 CALM1 CASQ2 PLN TRDN
15 cardiac muscle contraction GO:0060048 9.65 TNNT2 SCN5A RYR2 MYH7 CASQ2
16 negative regulation of calcium ion transmembrane transporter activity GO:1901020 9.63 PLN CALM1
17 regulation of heart rate GO:0002027 9.32 SCN5A RYR2 MYH7 CASQ2 CALM1

Molecular functions related to Cardiac Arrest according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane transporter binding GO:0044325 9.17 TRDN SCN5A RYR2 CALM1

Sources for Cardiac Arrest

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....